Home > News > featured news > A New Way To “Wrap” Liquid Medication

A New Way To “Wrap” Liquid Medication

Technology Networks | October 23, 2019

Researchers have developed a faster, cheaper way to coat liquid medication, an invention that could improve how drugs are delivered in the body. The new encapsulation technology, developed by engineers at the University of Waterloo, uses gravity and other natural forces to wrap drops as they fall through a thin layer of liquid shell floating on a base liquid. Once hardened, or cured, by exposure to ultraviolet light, the shell houses and protects the liquid core inside. “It is a very simple technique that requires almost no energy – and it is extremely rapid,” said Sushanta Mitra, executive director of the Waterloo Institute for Nanotechnology. “Encapsulation takes place in milliseconds.” When the liquid core is required – after reaching a particular area of the body for targeted drug delivery, for instance – the shell is designed to dissolve and release its contents. Mitra said the system’s simplicity enables much more economical production of capsules than current methods, which include machines that wrap drops with thin gel sheets and complex microfluidic processes. “We envision a very simple, rapid, mass-production system using syringes,” said Mitra, a professor of mechanical and mechatronics engineering who is cross-appointed in chemical engineering and physics and astronomy. “With a one-shot approach, you could produce thousands of these encapsulations.”

More featured news

Spotlight

Antibiotic Resistance: How common diseases become deadly

Coughing, runny nose, fever, vomiting, fatigue, and nausea all of these symptoms are common to both bacterial and viral infections. Historically speaking, both these kinds of microbes have led to deadly epidemics, wiping out millions of people from the face of the planet. Be it the Bubonic Plague, spread by the Yersinia Pestis bacteria or the Ebola Hemorrhagic Fever, caused by the ebolavirus – these pathogens have been responsible for countless fatalities and pronounced disability worldwide. In 1928, when Sir Alexander Fleming discovered the substance Penicillin, he made a breakthrough in the field of medical science.

Related News

BUSINESS INSIGHTS

Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions

Charles River Laboratories International, Inc. and Valo Health, LLC, | January 20, 2022

Charles River Laboratories International, Inc. and Valo Health, LLC, the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development capabilities to offer a new transformative, AI-enabled drug discovery and development platform. Recognizing the challenges of preclinical drug discovery, from high costs, time, and attrition rates, Valo and Charles River have joined forces to create enhanced drug discovery solutions that aim to transform the entire preclinical drug discovery process. Valo and Charles River intend to create and deliver offerings that produce preclinical assets with key performance characteristics optimized for client preferences. The partnership’s combined offerings will utilize Valo’s Opal Platform for small molecule development, which leverages a “closed-loop” in silico-experimental platform that rapidly iterates using program data to identify novel compounds, and leverages Charles River’s capabilities in all aspects of discovery optimization, including medicinal chemistry, ADME, biology, pharmacology, and ultimately safety testing and IND submission. The combination of Valo’s scientific innovation and deep technological expertise with Charles River’s end-to-end portfolio and industry-leading scientific bench has the potential to significantly accelerate a client’s discovery and development efforts by integrating data and compute to streamline and de-risk experimental science, enabling a faster and more effective process from de novo molecule design through lead optimization. The combined offering will be launched in the first half of 2022 and will be available exclusively from Charles River. About Valo Health Valo Health, LLC is a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence (“AI”) computation. As a digitally native company, Valo aims to full integrate human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CVS head of specialty pharmacy sees future of healthcare at home after Covid-19

Medcity news | May 26, 2020

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean more on them. The company has seen a surge in the use of its support services since the beginning of March.

New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion

AMR Action Fund | July 09, 2020

Today, more than 20 leading biopharmaceutical companies announced the launch of the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030. These treatments are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. The companies have raised so far nearly US$1 billion new funding to support clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients. The AMR Action Fund, an initiative of the international body representing the R&D pharmaceutical industry (International Federation of Pharmaceutical Manufacturers & Associations, IFPMA), was announced at simultaneous virtual launch events in Berlin, Germany, and Washington, D.C., USA, with a third event in Tokyo, Japan taking place on July 10.